Fennec Pharmaceuticals Completes Rolling Submission of NDA to U.S. FDA for Pedmark; Submits MAA to European Medicines Agency

Fennec Pharmaceuticals Completes Rolling Submission of NDA to U.S. FDA for Pedmark; Submits MAA to European Medicines Agency

Fennec Pharmaceuticals announced it has completed its rolling submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for Pedmark (a unique formulation of sodium thiosulfate) for intravenous use and submitted a Marketing Authorization...

Pin It on Pinterest